“The Three Dragons of AI Drug Development”: Metis Tech’s 6,900-Times Oversubscription Ushers in a New Era of AI Pharma Capital

Metis Tech set its H-share offer price at HK$10.50 per share, with a board lot size of 500 shares, making the minimum entry fee approximately HK$5,302.95. The Hong Kong public offering received over 6,900 times oversubscription, freezing more than HK$730 billion in capital, making it the year’s “subscription king” for Hong Kong IPOs so far in 2026.

The global offering attracted 18 strong cornerstone investors. BlackRock, UBS AM Singapore, Deerfield, RTW Funds, and China Asset Management (Hong Kong) collectively subscribed for US$148 million (approximately HK$1.159 billion), representing about 54.87% of the offering shares—a record for the AI pharma sector in Hong Kong IPOs. Their participation provides a solid demand base and signals strong international capital market interest and recognition for the emerging AI drug development field.

Metis Tech’s Financial Performance in the Years Leading Up to the IPO

As a pre-commercialization company, Metis Tech reported losses due to substantial R&D investments, though its financial data show positive trends.

In the three years before listing (2023-2025), Metis Tech accumulated a net loss of approximately RMB 1.473 billion. R&D expenses accounted for 55% to over 72% of total operating expenses.

During the same period, revenue grew from RMB 9.33 million to RMB 105 million. The 2025 growth was mainly driven by an upfront payment of RMB 100 million from out-licensing MTS-004, which represented over 95% of that year’s revenue, indicating that its technology platform has begun to generate returns. Excluding non-cash items, the adjusted net loss narrowed from RMB 347 million to RMB 180 million, showing continuous improvement.

Financially, the company had total available funds of approximately RMB 1.126 billion at the end of 2025. Together with the approximately HK$2.1 billion raised from the global offering, financial viability can be maintained for roughly 50 to 133 months, providing ample buffer for R&D and commercialization.

Metis Tech’s Shareholding Structure

Before listing, Metis Tech’s equity was relatively concentrated. Dr. Lai Caida, Dr. Wang Wenshou, Dr. Chen, and Scientia HK (acting in concert), together with employee incentive platforms, collectively held about 30.67%.

The company also successfully brought in pre-IPO investors such as CICC, HSG, and 5Y Capital, which together held approximately 32.08% of the issued share capital.

After listing, the public float represents about 71.85% of total issued shares, meeting the Stock Exchange’s requirements. H shares converted from non-listed shares held by existing shareholders are subject to a one-year lock-up period. The company has also applied for “Full Circulation” to enhance the international liquidity of its shares.

Use and Allocation of Metis Tech’s Offering Proceeds

Based on the offer price of HK$10.50 per share, Metis Tech raised HK$2.11 billion. The company plans to allocate approximately 50% of the net proceeds to core technology R&D for AI infrastructure and nanomaterials platforms, including NanoForge platform development, AI-enabled solutions, and in vivo validation of non-liver-targeted LNPs. About 20% will be used to advance clinical trials and IND filings for product pipelines such as MTS-201, MTS-105, and MTS-109.

The remaining funds—approximately 10% each—will be used for developing animal health and anti-aging solutions, building a global ecosystem (covering licensing, partnerships, and M&A in Europe, the Americas, and East Asia), and for working capital and general corporate purposes.

Metis Tech’s Major Business Segments and Market Footprint

Centered on its proprietary NanoForge AI nanomaterial platform, Metis Tech provides integrated solutions for small-molecule formulations, lipid nanoparticle delivery, and mRNA sequence design. These capabilities enable rapid optimization, organ targeting, and cross-species applications. The company focuses on high-value therapeutic areas such as oncology, immunology, metabolism, and the central nervous system. Its largest customer accounted for over 95% of revenue in 2025, and the company is actively diversifying its partnerships.

Industry data show that global AI-enabled pharmaceutical R&D spending is expected to reach US$123.9 billion by 2035, while the nanomedicine market is projected to hit US$585.4 billion over the same period, offering vast growth potential. The company has established over 30 global partnerships, with some contracts having potential values ranging from US$345 million to US$512 million.

Metis Tech’s strengths lie in its proprietary platform technology, dual-drive business model, and cross-industry expansion capabilities. NanoForge integrates one of the world’s largest ionizable lipid libraries and proprietary AI models to achieve efficient screening and precise design. The MTS-004 licensing agreement includes milestone payments of up to RMB 1.845 billion. The company has also extended its technology to the animal health sector.

Currently, Metis generates most of its revenue from the Chinese market but is actively pursuing globalization, aiming to cover Europe, the Americas, the Middle East, and East Asia. The company has achieved precise delivery to eight organs—including the liver, lungs, muscles, heart, brain, immune organs, gastrointestinal tract, and tumors—providing a broad technical foundation for pipeline indication expansion.

Metis Tech’s Advantages and Challenges

Metis Tech’s advantages are evident across multiple dimensions. Technologically, the company possesses one of the world’s largest ionizable lipid libraries and proprietary AI models, capable of predicting over 20 key indicators with high precision. This reduces preclinical formulation development time from the traditional one to two years to less than three months.

At the platform level, leveraging the biological commonalities of nanomaterials, its business has extended into pet anti-aging and animal health, transforming it into a cross-species life sciences technology platform.

On the shareholder front, top-tier institutions such as CICC, Sequoia, and PICC hold long-term stakes, while BlackRock and UBS participate as cornerstone investors. The company has also established partnerships with more than 30 global pharmaceutical and biotech companies.

However, Metis Tech also faces multiple challenges. First, the company is still in a pre-commercialization stage, with most pipelines in preclinical or early clinical phases. Failure of a core pipeline could severely impact its valuation.

Second, the company heavily relies on the NanoForge platform. If its technological edge is overtaken by international giants like Alnylam or Moderna, or by competitors like Insilico Medicine or XtalPi, its business could be fundamentally affected.

Third, its largest customer accounted for as much as 95.2% of 2025 revenue, making its revenue structure vulnerable due to high customer concentration. Regarding international trade policies, potential tightening of U.S. technology investment restrictions on China could also affect the company’s future fundraising and access to advanced technologies.

Metis Tech’s Short- and Long-Term Strategic Plans After Listing

In the one to two years following listing, Metis Tech’s core goal is to accelerate its transition to a commercial-stage company, expected to be achieved by May 2028. This transition depends on converting platform partnerships into licensing revenue, MTS-004 milestone payments, and new licensing deals. The company plans to file INDs for MTS-105 and MTS-109 in 2026 and initiate Phase I trials for MTS-201, while deepening existing collaborations to expand single assets into multi-asset, long-term strategic partnerships.

In the long term, its strategy focuses on technological deepening, ecosystem building, and global expansion. Technologically, Metis aims to extend its AI capabilities from lipid design to protein engineering, creating end-to-end solutions. On the ecosystem front, it plans to center on nanomaterials, covering human therapeutics, animal health, and anti-aging—having already signed a joint venture agreement with a leading pet healthcare group.

Regarding globalization, the company plans to establish presence in Europe, the Americas, the Middle East, and East Asia, enhance liquidity through Full Circulation of H shares, and strive to become a globally trusted innovation partner for AI-powered nanomaterials.

Metis Tech’s Prospects in Hong Kong

Following its listing in Hong Kong, Metis Tech is expected to further strengthen Hong Kong’s position as a global biotech listing hub. Its oversubscription and strong first-day price surge demonstrate the Hong Kong market’s ability to embrace and price cutting-edge AI pharma companies, which will attract more similar firms to list in Hong Kong, creating a clustering effect. Meanwhile, Full Circulation of H shares and the participation of top-tier international cornerstone investors will help enhance Hong Kong stock liquidity, attract long-term funds, and optimize market sector structure, increasing the market capitalization share of “new productive forces” enterprises.

Furthermore, Metis Tech’s listing may drive deeper discussions in the Hong Kong market regarding valuation frameworks for pre-commercialization companies. As a company still in preclinical and early clinical stages, its first-day market cap significantly exceeded its offering size, reflecting strong market optimism. This will encourage market participants and regulators to further refine disclosure standards and valuation frameworks for pre-commercialization biotech companies, laying a more solid institutional foundation for the sustainable development of Hong Kong’s capital market.